Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

Health

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

Tue, Jun 17, 2025 0 Comments

Audio By Carbonatix

Enlarge

(Reuters) -Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday.

Verve is developing therapies targeting genes that regulate cholesterol in the liver.

(Reporting by Sriparna Roy in Bengaluru; Editing by Pooja Desai)

Previous Tennis-Britain’s Boulter says she has received death threats

Next Kremlin says it sees that Israel does not want mediation efforts with Iran amid ‘galloping escalation’

Salem News Channel | Today

More Health Headlines

Other News to Consider

Follow SRNNews.com

on Facebook

@SRNNews

Subscribe to our Newsletters RSS Feeds

Salem Media, our partners, and affiliates use cookies and similar technologies to enhance your browsing experience, analyze site traffic, personalize site content, and deliver relevant video recommendations. By using this website and continuing to navigate, you consent to our use of such technologies and the sharing of video viewing activity with third-party partners in accordance with the Video Privacy Protection Act and other privacy laws. Privacy Policy

X CLOSE

Email to a Friend

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

(Reuters) -Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver. (Reporting by Sriparna Roy in Bengaluru; Editing by Pooja Desai)

X close